GLP-1 & Heart Health: Lifestyle Habits for Type 2 Diabetes

People with type 2 diabetes who combine healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications experience a greater reduction in cardiovascular risk than those relying on medication alone or lifestyle changes alone, according to a preliminary study presented at the American Heart Association’s Scientific Sessions 2025.

The research, presented November 3, 2025, indicated that individuals with type 2 diabetes who adhered to at least six healthy lifestyle habits while taking GLP-1 RA medications had a 50% lower risk of major adverse cardiovascular events – including heart attack, stroke, and cardiovascular disease-related death – compared to veterans with lower adherence to healthy habits receiving standard diabetes care without GLP-1 RAs.

Complementary Strategies for Cardiovascular Health

Researchers examined data from over 63,000 military veterans with type 2 diabetes. The findings underscore the importance of lifestyle modifications alongside pharmacological interventions for managing diabetes and reducing cardiovascular risk. “Lifestyle modifications are recommended as the cornerstone for preventing and managing Type 2 diabetes,” said lead study author, Xuan-Mai Nguyen, M.D., Ph.D.

A separate study, published February 25, 2026, in The Lancet Diabetes & Endocrinology, reached similar conclusions. Researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System found that using a GLP-1 receptor agonist in combination with healthy lifestyle habits significantly lowered the risk of poor cardiovascular health in individuals with type 2 diabetes.

Frank Hu, Fredrick J. Stare Professor of Nutrition and Epidemiology and chair of the Department of Nutrition at Harvard, emphasized that even with the availability of effective GLP-1 medications, lifestyle habits remain crucial for diabetes management and cardiovascular risk reduction.

“Our findings underscore that, even in the era of highly effective GLP-1 pharmacotherapy, lifestyle habits remain central to diabetes management and cardiovascular risk reduction and can substantially amplify the benefits of modern medications.”

Frank Hu, Fredrick J. Stare Professor of Nutrition and Epidemiology and chair of the Department of Nutrition, Harvard T.H. Chan School of Public Health

Study Details and Methodology

The Harvard study analyzed the lifestyle habits, GLP-1 RA usage, and cardiovascular health outcomes of more than 98,000 adults living with type 2 diabetes and without prior cardiovascular disease. Data was drawn from the Veterans Affairs’ Million Veteran Program, spanning from 2011 to 2023.

The American Heart Association study focused on military veterans with type 2 diabetes who were taking GLP-1 RA medications. Researchers assessed adherence to healthy lifestyle habits and tracked the incidence of major adverse cardiovascular events.

What Constitutes a ‘Healthy Lifestyle’?

While the studies did not explicitly define the six healthy lifestyle habits, general recommendations for managing type 2 diabetes include regular physical activity, a balanced diet rich in fruits, vegetables, and whole grains, maintaining a healthy weight, getting adequate sleep, managing stress, and avoiding smoking.

The Harvard study highlighted the complementary nature of these strategies, suggesting that lifestyle interventions and GLP-1 RAs work synergistically to improve cardiovascular outcomes. In other words that the benefits of medication are enhanced when combined with positive lifestyle changes, and vice versa.

Important Considerations

the American Heart Association study was presented as a research abstract and has not yet undergone peer review. The findings are considered preliminary until published in a peer-reviewed scientific journal. However, the results align with growing evidence supporting the holistic management of type 2 diabetes.

Both studies emphasize that a comprehensive approach – combining medication with lifestyle modifications – is the most effective strategy for reducing cardiovascular risk in individuals with type 2 diabetes. Further research is needed to determine the optimal combination of lifestyle interventions and pharmacological treatments for different patient populations.